TK1 activity has already been analyzed in locally advanced and/or metastatic BC patients under CDK4/6i therapy38,39,41,42 and these studies confirm that TK1 activity at baseline significantly correlates with PFS38,39,41,42, except for the TREND study40 that only included 43 locally advanced but no mBC patients. This evidence concerns the gene CDK4 and breast cancer.